Published Date: 16 Feb 2023
Chatbots have shields to control misinformation, but it will continue to be a game.
Read Full NewsSusan Corbridge, PhD, and Alanna Kavannagh, MSN, CCRN, discuss the role of advanced practice providers on the evolving pulmonary and critical care teams during CHEST 2025.
The phase 3 study aims to confirm findings from the HEALEY ALS platform trial in patients with early-stage rapidly progressive ALS, which suggested potential benefits of pridopidine across multiple domains.
Holzem spoke in this interview about several additional highlights from her session at SDPA Fall regarding red flags in dermatology and when to admit from the clinic.
Key Skin Cancer Terms Not Understood by Almost 1/3 of Patients Surveyed
1.
Glofitamab Regimen Improves Survival in DLBCL
2.
high response rate when using a bispecific antibody to treat R/R multiple myeloma.
3.
Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.
4.
Muscular strength and good physical fitness linked to lower risk of death in people with cancer
5.
Year in Review: Multiple Myeloma
1.
Liquid Biopsy: A Game-Changer in T-Cell Lymphoma Detection and Management
2.
Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results
3.
Breaking Down the Different Types of Lymphoma: What You Need to Know
4.
What You Need to Know About Correcting Calcium Levels in Patients with Low Albumin
5.
Case Study: Personalized Medicine Based on Genetic Profiling in Oncology
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
4.
Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment
5.
Efficient Management of First line ALK-rearranged NSCLC - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation